The Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company announced a decade-long R&D effort to discover new applications for induced pluripotent stem cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer immunotherapy, according to a press release.
Samsung, along with several other electronics conglomerates, is working to puzzle out what's next in mobile healthcare. A growing foothold in healthcare could aid these companies, which are vulnerable to the vagaries of eroding profit margins and rapidly evolving technology.
Swedish contract drug developer Recipharm has signed a deal with Virginia's Synthonics, investing in the biotech and lending its expertise in the development of new compounds.
Iris Pharma and Oculos Clinical Research, two CROs focused on the eye, have inked a strategic alliance to boost their profiles in the contracting world.
U.S. contractor Aptuit has signed a deal with Italy's Axxam to team up on early-stage R&D services, pooling their resources to better compete for projects.
TVM Capital Life Science moved quickly to tap a new $50 million venture capital fund with investment from Chinese partner Lummy Co. in a licensing deal for an oncology dendritic vaccine.
Alibaba Group Holding aims to ramp up fledgling online drug sales in China by placing online drug retailer Tmall under its listed healthcare unit in a shuffle estimated at $2.51 billion, the company said in a press release.
A promising angiogenic gene therapy candidate in development for nearly two decades has drawn in further investment from China-based Shenzhen Qianhai Taxus Industry Capital Management, picking up a 15% stake in Angionetics, a newly formed subsidiary of Taxus Cardium Pharmaceuticals Group.
Japan's RegImmune has joined with Pfizer and the former Juvenile Diabetes Research Foundation in a partnership to collaborate on research for an antigen-specific preventative for Type 1 diabetes. Financial arrangements were not disclosed, but Pfizer is to provide finances and expertise.
San Diego biotech Ichor Medical Systems stands to earn up to $85 million, plus royalties, if its new partnership with Johnson & Johnson's Janssen hits the right notes. The companies announced plans this week to develop DNA vaccines for hepatitis B using Ichor's TriGrid electroporation technology for clinical administration.